Aptevo Therapeutics Inc
APVO2.590USD
-0.090-3.36%
取引時間 （ET）15分遅れの株価
3.78M時価総額
損失額直近12ヶ月PER
詳細情報 Aptevo Therapeutics Inc 企業名
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. It has developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs. Its lead clinical candidates, APVO436 and ALG.APV-527, and preclinical candidates, APVO603 and APVO711, are developed using its ADAPTIR modular protein technology platform. Its preclinical candidate APVO442 is developed using its ADAPTIR-FLEX modular protein technology platform. APVO436 is a bispecific ADAPTIR that is designed to engage CD3 and CD123 to redirect T-cells to destroy leukemia cells expressing the target CD123 molecule on their surface. ALG.APV-527 is a novel investigational bispecific ADAPTIR candidate. APVO603 is a preclinical dual agonist bispecific ADAPTIR candidate designed to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family.
企業情報
企業コードAPVO
会社名Aptevo Therapeutics Inc
上場日Jul 20, 2016
最高経営責任者「CEO」Mr. Marvin L. White
従業員数37
証券種類Ordinary Share
決算期末Jul 20
本社所在地2401 4th Ave Ste 1050
都市SEATTLE
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号98121-3460
電話番号12068380500
ウェブサイトhttps://aptevotherapeutics.com/
企業コードAPVO
上場日Jul 20, 2016
最高経営責任者「CEO」Mr. Marvin L. White
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Marvin L. White
Mr. Marvin L. White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
43.00
+30.30%
Mr. Jeffrey G. Lamothe
Mr. Jeffrey G. Lamothe
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
23.00
+27.78%
Ms. Barbara Lopez Kunz
Ms. Barbara Lopez Kunz
Independent Director
Independent Director
1.00
--
Dr. Zsolt Harsanyi, Ph.D.
Dr. Zsolt Harsanyi, Ph.D.
Independent Director
Independent Director
1.00
--
Dr. John E. Niederhuber, M.D.
Dr. John E. Niederhuber, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.00
--
Ms. So Young Kwon
Ms. So Young Kwon
Senior Vice President, General Counsel, Business Development and Corporate Affairs
Senior Vice President, General Counsel, Business Development and Corporate Affairs
--
--
Ms. Daphne L. Taylor
Ms. Daphne L. Taylor
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Mr. Daniel J. Abdun-Nabi, J.D.
Mr. Daniel J. Abdun-Nabi, J.D.
Independent Director
Independent Director
--
--
Mr. Grady Grant, III
Mr. Grady Grant, III
Independent Director
Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Marvin L. White
Mr. Marvin L. White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
43.00
+30.30%
Mr. Jeffrey G. Lamothe
Mr. Jeffrey G. Lamothe
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
23.00
+27.78%
Ms. Barbara Lopez Kunz
Ms. Barbara Lopez Kunz
Independent Director
Independent Director
1.00
--
Dr. Zsolt Harsanyi, Ph.D.
Dr. Zsolt Harsanyi, Ph.D.
Independent Director
Independent Director
1.00
--
Dr. John E. Niederhuber, M.D.
Dr. John E. Niederhuber, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.00
--
Ms. So Young Kwon
Ms. So Young Kwon
Senior Vice President, General Counsel, Business Development and Corporate Affairs
Senior Vice President, General Counsel, Business Development and Corporate Affairs
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Wed, Jul 23
更新時刻: Wed, Jul 23
株主統計
種類
株主統計
株主統計
比率
Schiketanz Capital Advisors GmbH
0.02%
Geode Capital Management, L.L.C.
0.02%
Other
99.96%
株主統計
株主統計
比率
Schiketanz Capital Advisors GmbH
0.02%
Geode Capital Management, L.L.C.
0.02%
Other
99.96%
種類
株主統計
比率
Investment Advisor
0.02%
Investment Advisor/Hedge Fund
0.02%
Research Firm
0.01%
Other
99.95%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
37
1.61K
0.06%
-24.39K
2025Q1
50
1.38K
0.06%
-4.41K
2024Q4
49
48.74K
3.37%
-20.87K
2024Q3
46
34.83K
7.56%
-18.81K
2024Q2
48
53.21K
48.29%
+52.02K
2024Q1
49
188.00
1.03%
-1.27K
2023Q4
51
1.27K
10.69%
-1.06K
2023Q3
56
2.18K
24.99%
+1.07K
2023Q2
60
629.00
13.58%
-1.76K
2023Q1
67
602.00
13.71%
-1.90K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Schiketanz Capital Advisors GmbH
290.00
0.01%
+290.00
--
Jan 31, 2025
Geode Capital Management, L.L.C.
526.00
0.02%
+526.00
--
Mar 31, 2025
Tower Research Capital LLC
163.00
0.01%
+109.00
+201.85%
Mar 31, 2025
Clear Street LLC
140.00
0%
+140.00
--
Mar 31, 2025
BofA Global Research (US)
116.00
0%
+116.00
--
Mar 31, 2025
White (Marvin L)
3.00
0%
+1.00
+50.00%
Apr 04, 2025
SBI Securities Co., Ltd.
35.00
0%
+28.00
+400.00%
Mar 31, 2025
Lamothe (Jeffrey G)
2.00
0%
--
--
Apr 04, 2025
Kwon (SoYoung)
1.00
0%
--
--
Apr 04, 2025
詳細を見る
関連ETF
更新時刻: Sat, Aug 2
更新時刻: Sat, Aug 2
銘柄名
比率
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
Nov 29, 2024
Merger
37<1
Nov 29, 2024
Merger
37<1
Nov 29, 2024
Merger
37<1
Nov 29, 2024
Merger
37<1
Mar 04, 2024
Merger
44<1
Mar 04, 2024
Merger
44<1
日付
種類
比率
Nov 29, 2024
Merger
37<1
Nov 29, 2024
Merger
37<1
Nov 29, 2024
Merger
37<1
Nov 29, 2024
Merger
37<1
Mar 04, 2024
Merger
44<1
Mar 04, 2024
Merger
44<1
Mar 04, 2024
Merger
44<1
Mar 04, 2024
Merger
44<1
Mar 26, 2020
Merger
14<1
Mar 26, 2020
Merger
14<1
詳細を見る
